Aurora Therapeutics, a new startup co-founded by gene-editing pioneer Jennifer Doudna, is set to revolutionize the treatment landscape for rare diseases through tailored gene-editing solutions. The company’s mission is to leverage gene-editing technology, particularly the CRISPR system, to provide personalized treatments for patients with rare genetic conditions. This initiative follows the successful gene-editing treatment administered to an infant named KJ, which corrected a rare genetic mutation and potentially saved the child’s life.
Aurora Therapeutics’ approach is bolstered by a novel FDA regulatory pathway, known as the ‘plausible mechanism pathway,’ which enables the approval of personalized therapies for rare and life-threatening diseases based on data from a limited number of patients. This regulatory innovation, spearheaded by FDA officials Marty Makary and Vinay Prasad, streamlines the approval process for treatments tailored to rare diseases, where traditional large-scale trials are challenging due to limited patient populations.
The startup’s initial focus is on addressing phenylketonuria (PKU), a metabolic disorder detected at birth that results in harmful levels of phenylalanine in the body. By utilizing the new FDA pathway and harnessing gene-editing capabilities, Aurora Therapeutics aims to commercialize innovative treatments for PKU and expand its portfolio to include other rare diseases in the future.
Source: WIRED